This presentation describes work by the NGBS consortium, a public-private partnership of the Novartis Institute for Tropical Diseases, the Genomic Institute of the Novartis Research Foundation, the Biomedical Primates Research Center and the Swiss Tropical Public Health Institute, partly funded by MMV, to anticipate the threat of artemisinin resistance by developing replacement drugs of different types, and improve patient compliance by reducing pill burden and treatment duration. This led to the development of drug candidate NITD609, a spiroindolone, which appears promising and was expected to human trials in the first quarter of 2011.
Presentation from MMV-CRESIB Forum, Barcelona, Spain, 15 March 2010. Medicines for Malaria Venture, Geneva, Switzerland. 18 pp.
Spiroindolones: a new chemotype for the treatment of malaria